TY - JOUR
T1 - Therapeutics targeting the inflammasome after central nervous system injury
AU - De Rivero Vaccari, Juan Pablo
AU - Dietrich, W. Dalton
AU - Keane, Robert W.
N1 - Funding Information:
This work was supported by grants to J.P.d.R.V. ( American Heart Association 12SDG11970010 ) and to R.W.K. ( National Institute of Health Grant 1R42NS086274 ) and The Miami Project to Cure Paralysis.
Funding Information:
All authors have read the journal''s policy on disclosure of potential conflicts of interest. The authors declare that they are cofounders of InflamaCORE, limited liability company (LLC). This work was supported by grants to J.P.d.R.V. (American Heart Association 12SDG11970010) and to R.W.K. (National Institute of Health Grant 1R42NS086274) and The Miami Project to Cure Paralysis. All authors have read the journal''s authorship agreement and the manuscript has been reviewed and approved by all named authors.
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Innate immunity is part of the early response of the body to deal with tissue damage and infections. Because of the early nature of the innate immune inflammatory response, this inflammatory reaction represents an attractive option as a therapeutic target. The inflammasome is a component of the innate immune response involved in the activation of caspase 1 and the processing of pro-interleukin 1β. In this article, we discuss the therapeutic potential of the inflammasome after central nervous system (CNS) injury and stroke, as well as the basic knowledge we have gained so far regarding inflammasome activation in the CNS. In addition, we discuss some of the therapies available or under investigation for the treatment of brain injury, spinal cord injury, and stroke.
AB - Innate immunity is part of the early response of the body to deal with tissue damage and infections. Because of the early nature of the innate immune inflammatory response, this inflammatory reaction represents an attractive option as a therapeutic target. The inflammasome is a component of the innate immune response involved in the activation of caspase 1 and the processing of pro-interleukin 1β. In this article, we discuss the therapeutic potential of the inflammasome after central nervous system (CNS) injury and stroke, as well as the basic knowledge we have gained so far regarding inflammasome activation in the CNS. In addition, we discuss some of the therapies available or under investigation for the treatment of brain injury, spinal cord injury, and stroke.
UR - http://www.scopus.com/inward/record.url?scp=84952639919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952639919&partnerID=8YFLogxK
U2 - 10.1016/j.trsl.2015.05.003
DO - 10.1016/j.trsl.2015.05.003
M3 - Review article
C2 - 26024799
AN - SCOPUS:84952639919
VL - 167
SP - 35
EP - 45
JO - Translational Research
JF - Translational Research
SN - 1931-5244
IS - 1
ER -
